This inventor holds 4 USPTO granted patents and 4 published patent applications and 2 EPO patents. Top assignees: Genentech, Inc., Hoffmann-La Roche Inc., F. Hoffmann-La Roche Ag. Active years: 2019-2026.
Company Filing History:
2 out of 3,294 
2 out of 5,020 
1 out of 180 
Years Active: 2019-2026
Title: The Innovative Contributions of Tarik Ali Khan
Introduction
Tarik Ali Khan is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of cancer treatment through his innovative patent work. With a total of three patents to his name, Khan's research focuses on improving the administration of HER2 antibody formulations.
Latest Patents
Khan's latest patents include fixed dose HER2 antibody formulations designed for subcutaneous administration. These formulations are aimed at enhancing the treatment of cancer. They consist of fixed dose subcutaneous formulations of pertuzumab, as well as co-formulations of pertuzumab and trastuzumab. The innovative approach of these formulations is intended to improve patient outcomes in cancer therapy.
Career Highlights
Throughout his career, Tarik Ali Khan has worked with prominent companies in the pharmaceutical industry, including Genentech, Inc. and Hoffmann-La Roche Inc. His experience in these organizations has contributed to his expertise in developing effective cancer treatments.
Collaborations
Khan has collaborated with talented professionals in his field, including Jennifer Eng-Wong and Whitney Kirschbrown. These partnerships have likely played a role in the successful development of his patented formulations.
Conclusion
Tarik Ali Khan's work in the field of cancer treatment through innovative HER2 antibody formulations showcases his dedication to improving patient care. His contributions are significant and reflect the importance of innovation in medical research.